MIGRAINE IS a common, painful, and often disabling condition with major social, financial, and personal ramifications. Over the past decade, there have been major advancements in the treatment of migraine, most notably in the recognition of effective therapy that targets the vascular serotonin receptors of the 5-HT1B and 5HT1D types and the array of present and future triptans that serve as agonists in reacting with those receptors. The care of patients with migraine involves many approaches, but the triptans serve as one of the most effective and frequently used abortives for headache from which sufferers need and demand prompt and effective relief.
Whitaker JN. Triptans for Migraine Headache: Therapeutic Progress Meets a Heterogeneous Patient Response. Arch Neurol. 2001;58(9):1482–1483. doi:10.1001/archneur.58.9.1482
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: